Platt Heather L.

Podsumowanie dorobku w bazie danych

2
publikacji (2019–2026)
11,861
łączny Impact Factor
300
łącznie punktów MNiSW

Identyfikatory

BPP ID
43380

Publikacje w latach

10

Punkty MNiSW w latach

200,000

Impact Factor w latach

8,3000

Statystyki wg charakteru

Charakter formalnyLiczba prac
2

Najczęstsi współautorzy

  • (1)
  • (1)
  • (1)
  • (1)
  • (1)
  • (1)
  • (1)
  • (1)
  • (1)
  • (1)
Zobacz pełną sieć powiązań

Wyszukaj publikacje autora

Bez zaznaczonych filtrów wyszukiwanie pokaże wszystkie prace autora. Zaznacz typy, lata lub jednostki, żeby zawęzić wyniki.

Typ publikacji
Lata
Jednostki

Najlepsze prace (punkty MNiSW)

  1. A phase 3, randomized trial investigating the safety, tolerability, and immunogenicity of V116, an adult-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve ndults 18-64 years of age at increased risk of pneumococcal disease, STRIDE-8. [AUT. KORESP.] PAUL T. SCOTT, [AUT.] JAYANI PATHIRANA, AKIRA KATO, RICHARD TYTUS, CARLOS M. PEREZ, NIGEL LESLIE GILCHRIST, HIDEMI KANOU, KWANG HA YOO, GRZEGORZ KANIA, MICHAEL NISSEN, AMY FALK RUSSELL, DOREEN FERNSLER, MUHAMMAD WALEED, JIANING LI, ULRIKE K. BUCHWALD, HEATHER L. PLATT, the STRIDE-8 Study Group. Clin. Infect. Dis. 2026 vol. 82 nr 2 s. e217-e226, bibliogr. poz. 39. DOI: 10.1093/cid/ciaf604
  2. Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. [AUT. KORESP.] ERIC LAWITZ, [AUT.] EDWARD GANE, JORDAN J. FELD, MARIA BUTI, GRAHAM R. FOSTER, MORDECHAI RABINOVITZ, EDUARD BURNEVICH, HELENA KATCHMAN, KRZYSZTOF TOMASIEWICZ, FRED LAHSER, BETH JACKSON, MELISSA SHAUGHNESSY, STEPHANIE KLOPFER, WENDY W. YEH, MICHAEL N. ROBERTSON, GEORGE J. HANNA, ELIAV BARR, HEATHER L. PLATT, ON BEHALF OF THE C‐BREEZE‐2 STUDY INVESTIGATORS. J. Viral Hepat. 2019 vol. 26 nr 9 s. 1127-1138, bibliogr. DOI: 10.1111/jvh.13132

Najlepsze prace (Impact Factor)

  1. A phase 3, randomized trial investigating the safety, tolerability, and immunogenicity of V116, an adult-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve ndults 18-64 years of age at increased risk of pneumococcal disease, STRIDE-8. [AUT. KORESP.] PAUL T. SCOTT, [AUT.] JAYANI PATHIRANA, AKIRA KATO, RICHARD TYTUS, CARLOS M. PEREZ, NIGEL LESLIE GILCHRIST, HIDEMI KANOU, KWANG HA YOO, GRZEGORZ KANIA, MICHAEL NISSEN, AMY FALK RUSSELL, DOREEN FERNSLER, MUHAMMAD WALEED, JIANING LI, ULRIKE K. BUCHWALD, HEATHER L. PLATT, the STRIDE-8 Study Group. Clin. Infect. Dis. 2026 vol. 82 nr 2 s. e217-e226, bibliogr. poz. 39. DOI: 10.1093/cid/ciaf604
  2. Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. [AUT. KORESP.] ERIC LAWITZ, [AUT.] EDWARD GANE, JORDAN J. FELD, MARIA BUTI, GRAHAM R. FOSTER, MORDECHAI RABINOVITZ, EDUARD BURNEVICH, HELENA KATCHMAN, KRZYSZTOF TOMASIEWICZ, FRED LAHSER, BETH JACKSON, MELISSA SHAUGHNESSY, STEPHANIE KLOPFER, WENDY W. YEH, MICHAEL N. ROBERTSON, GEORGE J. HANNA, ELIAV BARR, HEATHER L. PLATT, ON BEHALF OF THE C‐BREEZE‐2 STUDY INVESTIGATORS. J. Viral Hepat. 2019 vol. 26 nr 9 s. 1127-1138, bibliogr. DOI: 10.1111/jvh.13132

Najnowsze artykuły

  1. A phase 3, randomized trial investigating the safety, tolerability, and immunogenicity of V116, an adult-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve ndults 18-64 years of age at increased risk of pneumococcal disease, STRIDE-8. [AUT. KORESP.] PAUL T. SCOTT, [AUT.] JAYANI PATHIRANA, AKIRA KATO, RICHARD TYTUS, CARLOS M. PEREZ, NIGEL LESLIE GILCHRIST, HIDEMI KANOU, KWANG HA YOO, GRZEGORZ KANIA, MICHAEL NISSEN, AMY FALK RUSSELL, DOREEN FERNSLER, MUHAMMAD WALEED, JIANING LI, ULRIKE K. BUCHWALD, HEATHER L. PLATT, the STRIDE-8 Study Group. Clin. Infect. Dis. 2026 vol. 82 nr 2 s. e217-e226, bibliogr. poz. 39. DOI: 10.1093/cid/ciaf604
  2. Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. [AUT. KORESP.] ERIC LAWITZ, [AUT.] EDWARD GANE, JORDAN J. FELD, MARIA BUTI, GRAHAM R. FOSTER, MORDECHAI RABINOVITZ, EDUARD BURNEVICH, HELENA KATCHMAN, KRZYSZTOF TOMASIEWICZ, FRED LAHSER, BETH JACKSON, MELISSA SHAUGHNESSY, STEPHANIE KLOPFER, WENDY W. YEH, MICHAEL N. ROBERTSON, GEORGE J. HANNA, ELIAV BARR, HEATHER L. PLATT, ON BEHALF OF THE C‐BREEZE‐2 STUDY INVESTIGATORS. J. Viral Hepat. 2019 vol. 26 nr 9 s. 1127-1138, bibliogr. DOI: 10.1111/jvh.13132

Ostatnio edytowane

  1. A phase 3, randomized trial investigating the safety, tolerability, and immunogenicity of V116, an adult-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve ndults 18-64 years of age at increased risk of pneumococcal disease, STRIDE-8. [AUT. KORESP.] PAUL T. SCOTT, [AUT.] JAYANI PATHIRANA, AKIRA KATO, RICHARD TYTUS, CARLOS M. PEREZ, NIGEL LESLIE GILCHRIST, HIDEMI KANOU, KWANG HA YOO, GRZEGORZ KANIA, MICHAEL NISSEN, AMY FALK RUSSELL, DOREEN FERNSLER, MUHAMMAD WALEED, JIANING LI, ULRIKE K. BUCHWALD, HEATHER L. PLATT, the STRIDE-8 Study Group. Clin. Infect. Dis. 2026 vol. 82 nr 2 s. e217-e226, bibliogr. poz. 39. DOI: 10.1093/cid/ciaf604
  2. Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. [AUT. KORESP.] ERIC LAWITZ, [AUT.] EDWARD GANE, JORDAN J. FELD, MARIA BUTI, GRAHAM R. FOSTER, MORDECHAI RABINOVITZ, EDUARD BURNEVICH, HELENA KATCHMAN, KRZYSZTOF TOMASIEWICZ, FRED LAHSER, BETH JACKSON, MELISSA SHAUGHNESSY, STEPHANIE KLOPFER, WENDY W. YEH, MICHAEL N. ROBERTSON, GEORGE J. HANNA, ELIAV BARR, HEATHER L. PLATT, ON BEHALF OF THE C‐BREEZE‐2 STUDY INVESTIGATORS. J. Viral Hepat. 2019 vol. 26 nr 9 s. 1127-1138, bibliogr. DOI: 10.1111/jvh.13132